VOYA Investment Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-21,295
Closed -$63K 2935
2022
Q1
$63K Buy
21,295
+2,795
+15% +$10.5K ﹤0.01% 2572
2021
Q4
$83K Sell
18,500
-376
-2% -$1.78K ﹤0.01% 2692
2021
Q3
$92K Hold
18,876
﹤0.01% 2754
2021
Q2
$129K Sell
18,876
-1,468
-7% -$11.9K ﹤0.01% 2723
2021
Q1
$144K Hold
20,344
﹤0.01% 2607
2020
Q4
$127K Buy
20,344
+5,861
+40% +$34.5K ﹤0.01% 2520
2020
Q3
$78K Hold
14,483
﹤0.01% 2384
2020
Q2
$76K Sell
14,483
-2,706
-16% -$12K ﹤0.01% 2375
2020
Q1
$54K Sell
17,189
-1,952
-10% -$7.2K ﹤0.01% 2484
2019
Q4
$77K Buy
19,141
+5,989
+46% +$20.8K ﹤0.01% 2603
2019
Q3
$57K Hold
13,152
﹤0.01% 2485
2019
Q2
$52K Hold
13,152
﹤0.01% 2559
2019
Q1
$70K Hold
13,152
﹤0.01% 2486
2018
Q4
$67K Hold
13,152
﹤0.01% 2457
2018
Q3
$128K Hold
13,152
﹤0.01% 2455
2018
Q2
$134K Buy
13,152
+2,579
+24% +$29.2K ﹤0.01% 2460
2018
Q1
$137K Hold
10,573
﹤0.01% 2419
2017
Q4
$189K Hold
10,573
﹤0.01% 2363
2017
Q3
$265K Hold
10,573
﹤0.01% 2239
2017
Q2
$255K Buy
+10,573
New +$234K ﹤0.01% 2265

Other funds holding PRTK

VOYA Investment Management's PRTK Position: Q2 2022 in Review

VOYA Investment Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 21,295 shares — an estimated $63K sold.

VOYA Investment Management first reported a position in PRTK in Q2 2017 and held it in 20 quarters. The position peaked at $265K in Q3 2017. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

  • VOYA Investment Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • VOYA Investment Management sold 21,295 Paratek Pharmaceuticals, Inc. shares in Q2 2022, an estimated $63K.
  • VOYA Investment Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 20 quarters.
  • VOYA Investment Management's Paratek Pharmaceuticals, Inc. position peaked at $265K in Q3 2017.
  • 84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on VOYA Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.